ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
| Website | https://recodetx.com/ |
| Revenue | $14.8 million |
| Employees | 58 (55 on RocketReach) |
| Founded | 2015 |
| Technologies |
JavaScript
,
HTML
,
PHP
+18 more
(view full list)
|
| Industry | Biotechnology Research, Drug Delivery, Pharmaceuticals |
| Keywords | Mrna Therapeutics, Gene Editing, Gene Therapy, Lipid Nanoparticles, Targeted Drug Delivery, Next Generation Therapeutics, Drug Delivery, Therapeutic Delivery, Clinical Stage, Biotechnology, Pharmaceutical, Precision Medicine, Novel Therapeutics, Advanced Therapeutics |
| Competitors | Novartis, Pfizer, Amgen, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, Moderna Therapeutics, BioMarin Pharmaceutical Inc., Alnylam Pharmaceuticals, Akcea Therapeutics +39 more (view full list) |
Looking for a particular ReCode Therapeutics employee's phone or email?
The ReCode Therapeutics annual revenue was $14.8 million in 2026.
Shehnaaz Suliman is the President and Chief Executive Officer of ReCode Therapeutics.
55 people are employed at ReCode Therapeutics.